Skip to main content

Table 1 Cytotoxicity of BTZ, Ara-C and DSF/Cu2+ in AML cell lines

From: Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells

Cell lines AML Classification Age Type IC50 (nM) (Mean ± SD)
BTZ Ara-C DSF/Cu2+
CMK Acute Megakaryoblastic Leukemia 10 months Down Syndrome Relapse 4.9 ± 2.6 70 ± 30 105 ± 25
CMY Acute Megakaryoblastic Leukemia 21 months Down SyndromeRefractory 2.6 ± 0.6 1795 ± 391 72 ± 16
CMS Acute Megakaryoblastic Leukemia 2 years   4.3 ± 1.6 154 ± 21 82 ± 4.7
THP-1 Acute Monocytic Leukemia MLL-AF9 1 year Relapse 7.8 ± 3.3 3537 ± 331 79 ± 18
M-07e Acute Megakaryoblastic Leukemia 1 year   3.7 ± 0.8 24 ± 4.4 68 ± 22
AML-193 Acute Monocytic Leukemia 13 years Relapse 4.6 ± 3.1 414 ± 29.9 53 ± 12.7
Kasumi-1 AML t(8,21) 7 years 2nd relapse after BMT 6.7 ± 3.0 27.6 ± 2.5 89 ± 13
Molm-13 AML with Flt-3 ITD 20 years Relapse 6.8 ± 3.6 4 ± 1 98 ± 10
MV-4-11 Biphenotypic Myelomonocytic Leukemia FLT-3 ITD 10 years   3.4 ± 0.5 278 ± 73 50 ± 10
NB4 Acute Promyelocytic Leukemia 20 years Relapse 2.7 ± 1.4 123 ± 114 57 ± 5
HL-60 Acute Promyelocytic Leukemia 36 years   7.1 ± 1.5 424 ± 172 67 ± 19
KG-1a Acute Myeloid leukemia 59 years   17.0 ± 0.9 177 ± 43 79 ± 11
TF-1 Erythroleukemia 35 years   8.3 ± 2.1 75 ± 52 101 ± 21
HEL 92.1.7 Erythroleukemia 30 years   6.2 ± 2.9 102 ± 13 100 ± 8.5
  1. IC50 values are presented as mean ± standard deviation. Data represent at least three replicate experiments. Ara-C cytarabine, BTZ bortezomib, DSF disulfiram